Reduction of falls and osteoporotic fractures: Plain vitamin D or D-hormone analogs?

Geriatrics and Gerontology International

Volumn 8, Issue SUPPL. 1, 2008, Pages

  Schacht, Erich ^a  

^a ZORG   (Switzerland)

Author keywords

Alfacalcidol; Calcitriol; Falls; Fractures; Vitamin D

Indexed keywords

EID: 57249108578     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2007.00400.x     Document Type: Conference Paper

References (71)

1. Runge M, Schacht E. Multifactorial Pathogenesis of Falls as a Basis for Multifactorial Interventions. J Musculoskelet Neuronal Interact 2005; 5: 127-134.
2. Kaptoge S, Benevolenskaya LI, Bhalla AK et al. Low BMD is less predictive than reported falls for future limb fractures in women across Europe: Results from the European Prospective Osteoporosis Study. Bone 2005; 36: 387-398.
3. Wainwright SA, Marshall LM, Ensrud KE et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005; 90: 2787-2793.
4. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 1999; 65: 317-327.
5. Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and Interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003; 88: 2019-2025.
6. Stein MS, Wark JD, Scherer SC et al. Falls related to vitamin D and parathyroid hormone in Australian nursing home and hostel. J Am Geriatr Soc 1999; 47: 1195-1201.
7. Dukas LC, Schacht E. Low creatinine clearance, glucocorticoid treatment, rheumatoid arthritis - different etiologies for low D-Hormone syndrome and its associated increased risk for falls. J Rheumatol 2005; 32: 44-46.
8. Bischoff HA, Borchers M, Gudat F et al. In situ detection of 1,25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochemistry 2001; 33: 19-24.
9. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev 1986; 784: 434-448.
10. Endo I, Inoue D, Mitsui T et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003; 144: 5138-5144.
11. Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 2004; 19: 265-269.
12. Bischoff HA, Stähelin HB, Urscheler N et al. Muscle strength in the elderly: Its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999; 80: 54-58.
13. Dukas L, Staehelin HB, Schacht E, Bischoff HA. Better functional mobility in community-dwelling elderly is related to D-Hormone serum levels and to daily calcium intake. J Nutr Health Aging 2005; 9: 347-351.
14. Nevitt MC, Cummings SR, Stone KL et al. Risk factors for a first-incident radiographic vertebral fracture in women ≥65 years of age: The study of osteoporotic fractures. J Bone Miner Res 2005; 20: 131-140.
15. Frost HM. Defining osteopenias and osteoporoses: Another view (with insights from a new paradigm). Bone 1997; 20: 385-391.
16. Haines TP, Bennel KL, Osborne RH, Hill KD. Effectiveness of targeted falls prevention programme in subacute hospital setting: Randomised controlled trial. BMJ 2004; 328: 1-6.
17. Chang JT, Morton SC, Rubenstein LZ et al. Interventions for the prevention of falls in older adults: Systematic review and meta-analysis of randomised clinical trials. BMJ 2004; 328: 1-7.
18. Richy F, Ethgen O, Bruyere O, Reginster J-Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: A meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15: 301-310.
19. Argiles JM, Alvarez B, Carbo N, Busquets S, Van Royen M, Lopez-Soriano FJ. The divergent effects of tumour necrosis factor-alpha on skeletal muscle: Implications in wasting. Eur Cytokine Netw 2000; 11: 552-559.
20. Scharla SH, Schacht E, Lempert UG. Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J Rheumatol 2005; 32: 26-32.
21. Inanir A, Ozoran K, Tutkak H, Mermerci B. The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis. J Int Med Res 2004; 32: 570-582.
22. DeLuca HF, Cantorna MT. Vitamin D. Its role and uses in immunology. FASEB J 2001; 15: 2579-2585.
23. 2 microglobulin in patients with osteoporosis. Calcif Tissue Int 1997; 60: 236-239.
24. Schacht E, Richy R, Reginster J-Y. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 2005; 5: 273-284.
25. Orimo H, Schacht E. The D-Hormone analog alfacalcidol: The pioneer beyond the horizon of osteoporosis treatment. J Rheumatol 2005; 32: 4-10.
26. Sörensen OH, Lund BI, Saltin B et al. Myopathy in bone loss of ageing: Improvement by treatment with 1-alpha-hydroxycholecalciferol and calcium. Clin Sci 1979; 56: 157-161.
27. Verhaar HJJ, Samson MM, Jansen PAF, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res 2000; 12: 455-460.
28. Gallagher JC. The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 2004; 89-90: 497-501.
29. Koike T, Okawa T, Wada M, Kita T, Takaoka K. Effects of a long-term alfacalcidol or calcitonin administration on body sway in Japanese elderly women. J Bone Mineral Res 2003; 18: S168.
30. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001; 86: 3618-3628.
31. Dukas L, Bischoff HA, Lindpaintner LS et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52: 230-236.
32. Dukas LC, Schacht E, Mazor Z, Stähelin HB. A new significant and independent risk factor for falls in elderly men and women: A low creatinine clearance of less than 65 mL/min. Osteoporos Int 2005; 16: 332-338.
33. Dukas L, Schacht E, Mazor Z, Stähelin HB. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 mL/min. Osteoporos Int 2005; 16: 198-203.
34. Dukas L, Schacht E, Stähelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 mL/min is a risk factor for falls and fractures. Osteoporos Int 2005; 16: 1683-1690.
35. Gallagher JC, Rapuri PB, Smith LM. An age related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol. J Bone Miner Res 2005; 20: S387.
36. Gallagher JC, Rapuri PB, Smith LM. An Age-Related Decrease in Creatinine Clearance is Associated with an Increase in Number of Falls in Untreated Women But Not in Women Receiving Calcitriol Treatment. J Clin Endocrinal Metab 2007; 92: 51-58.
37. Ensrud K, Lui L, Taylor BC et al. for the Study of Osteoporotic Fractures Research Group. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167: 133-139.
38. 3. J Bone Miner Metab 1992; 10: 184-188.
39. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54: 370-376.
40. Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of post-menopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326: 357-362.
41. Tanizawa T, Imura K, Ishii Y et al. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: A retrospective study. Osteoporos Int 1999; 9: 163-170.
42. 3 and calcium supplementation. Stroke 1997; 28: 736-739.
43. 3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66: 64-68.
44. Papadimitropoulos E, Wells G, Shea B et al. The osteoporosis methodology group, and the osteoporosis research advisory group. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 560-569.
45. Ringe JD, Schacht E. Prevention and therapy of osteoporosis. The roles of plain vitamin D and alfacalcidol. Rheumat Int 2004; 24: 189-197.
46. Richy F, Schacht E, Bruyère O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. Calcif Tissue Int 2005; 76: 176-186.
47. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323.
48. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, The Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-578.
49. 3 in Japan. Akt Rheumatol 1994; 19: 27-30.
50. Nuti R, Bianchi G, Brandi ML et al. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int 2006; 26: 445-453.
51. Wong M. Raloxifene does not affect neuromuscular-related risk factors for falling or the incidence of falls in postmenopausal women with osteporosis. J Am Geriatr Soc 2000; 48: S44.
52. Krueger K, Yaffe K, Sarkar S, Cox D, Fisher M. Effect of 3 years raloxifene therapy on neuromotor function and the incidence of falls in osteoporotic postmenopausal women. J Am Geriatr Soc 2000; 48: S43.
53. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-340.
54. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC et al. Effect of vitamin D on falls. A meta-analysis. JAMA 2004; 291: 1999-2006.
55. Latham NK, Anderson CS, Lee A, Bennett DA, Moseley A, Cameron ID. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: The Frailty Interventions Trial in Elderly Subjects (FITNESS). J Am Geriatr Soc 2003; 51: 291-299.
56. Chapuy M, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327: 1637-1642.
57. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400-406.
58. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-676.
59. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (Cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ 2003; 326: 469-475.
60. Smith H, Anderson F, Raphael H, Crozier S, Cooper C. Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial. Osteoporos Int 2004; 15: S8.
61. 3) for prevention of fractures in primary care. BMJ 2005; 330: 1003-1006.
62. 3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): A randomised placebo-controlled trial. Lancet 2005; 365: 1621-1628.
63. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation. A meta-analysis of randomized controlled trials. JAMA 2005; 293: 2257-2264.
64. Latham NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: A systematic review. J Am Geriatr Soc 2003; 51: 1219-1226.
65. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6: 162-169.
66. Nordin BEC, Need AG, Morris HA, Horowitz M. The special role of "Hormonal" forms of vitamin D in the treatment of osteoporosis. Calcif Tissue Int 1999; 65: 307-310.
67. Lau KHW, Baylink DJ. Vitamin D therapy of osteoporosis. Plain vitamin D therapy versus active vitamin D analog (D-Hormone) therapy. Calcif Tissue Int 1999; 65: 295-306.
68. 3 results from ligand-induced stabilization. J Biol Chem 1992; 267: 20082-20086.
69. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2004; 24: 63-70.
70. Miya K, Morimoto S, Fukuo K et al. Cognitive function and calcium related factors in elderly female subjects. Nippon Ronen Igakkai Zasshi 1991; 28: 34-39.
71. 3 concentrations associated with lower fall rates in older community-dwelling women. Osteoporos Int 2006; 17: 1318-1328.